Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Long-Term Investments: 2016-2024

Historic Long-Term Investments for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $5.0 million.

  • UroGen Pharma's Long-Term Investments fell 91.81% to $380,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $380,000, marking a year-over-year decrease of 91.81%. This contributed to the annual value of $5.0 million for FY2024, which is 11.55% up from last year.
  • Latest data reveals that UroGen Pharma reported Long-Term Investments of $5.0 million as of FY2024, which was up 11.55% from $4.5 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Long-Term Investments registered a high of $5.0 million during FY2024, and its lowest value of $223,000 during FY2022.
  • Its 3-year average for Long-Term Investments is $3.2 million, with a median of $4.5 million in 2023.
  • Its Long-Term Investments has fluctuated over the past 5 years, first tumbled by 96.10% in 2020, then soared by 1,918.83% in 2023.
  • UroGen Pharma's Long-Term Investments (Yearly) stood at $1.9 million in 2020, then slumped by 64.34% to $675,000 in 2021, then crashed by 66.96% to $223,000 in 2022, then surged by 1,918.83% to $4.5 million in 2023, then climbed by 11.55% to $5.0 million in 2024.